Please assess the completion status of the following clinical trial:

Trial Title: Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be ≥ 21 and \<80 years of age~2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV dysfunction, and clinical evidence of HF~3. Have a detectable area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any subendocardial involvement by cMRI~4. Have an EF ≤ 40% by cMRI~5. Be receiving guideline-driven medical therapy for heart failure at stable and tolerated doses for ≥ 1 month prior to consent. For beta-blockade stable is defined as no greater than a 50% reduction in dose or no more than a 100% increase in dose.~6. Be a candidate for cardiac catheterization~7. Have NYHA class I, II, or III heart failure symptoms~8. If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 hours prior to injection~Exclusion Criteria:~1. Indication for standard-of-care surgery (including valve surgery, placement of left-ventricular assist device, or imminent heart transplantation), coronary artery bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for the treatment of ischemic and/or valvular heart disease. Subjects who require or undergo PCI should undergo these procedures a minimum of 3 months in advance of randomization. Subjects who require or undergo CABG should undergo these procedures a minimum of 4 months in advance of randomization. In addition, subjects who develop a need for revascularization following enrollment should undergo revascularization without delay. Indication for imminent heart transplantation is defined as a high likelihood of transplant prior to collection of the 12 month study endpoint. Candidates cannot be UNOS status 1A or 1B, and they must have documented low probability of being transplanted~2. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2) severe (any valve) insufficiency/regurgitation within 12 months of consent~3. Aortic stenosis with valve area ≤ 1.5 cm2~4. History of ischemic or hemorrhagic stroke within 90 days of consent~5. History of a left ventricular remodeling surgical procedure utilizing prosthetic material~6. Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator with any of the following limitations/conditions:~   * manufactured before the year 2000~  * leads implanted \< 6 weeks prior to consent~  * non-transvenous epicardial, or abandoned leads~  * subcutaneous ICDs~  * leadless pacemakers~  * any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated~7. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD are not excluded)~8. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent~9. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)~10. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent~11. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent~12. Presence of LV thrombus~13. Evidence of active myocarditis~14. Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based predictive values~15. Baseline eGFR \<35 ml/min/1.73m2~16. Blood glucose levels (HbA1c) \>10%~17. Hematologic abnormality evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet count \< 100,000/ul~18. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the upper limit of normal (ULN)~19. Coagulopathy (INR ≥ 1.3) not due to a reversible cause (e.g., warfarin and/or Factor Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be excluded.~20. HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV)~21. Allergy to radiographic contrast material that cannot adequately be managed by premedication~22. Known history of anaphylactic reaction to penicillin or streptomycin~23. Received gene or cell-based therapy from any source within the previous 12 months~24. History of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in situ which have been definitively treated~25. Condition that limits lifespan to \< 1 year~26. History of drug abuse (illegal street drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months~27. Participation in an investigational therapeutic or device trial within 30 days of consent~28. Cognitive or language barriers that prohibit obtaining informed consent or any study elements~29. Pregnancy or lactation or plans to become pregnant in the next 12 months~30. Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow-up

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal Stem Cells (MSC) (Type: EXPERIMENTAL): Target dose of 150 million MSCs
- c-kit+ cells (Type: EXPERIMENTAL): Target dose of 5 million c-kit+ cells
- Combination Cells (MSC and c-kit+ cells) (Type: EXPERIMENTAL): Target dose of 150 million MSCs and 5 million c-kit+ cells
- Placebo (Plasmalyte A) (Type: PLACEBO_COMPARATOR): Plasmalyte A

Based on this trial design, predict the completion outcome and termination type (if applicable).